Human ApoE3

<strong>Human ApoE3</strong>_x000D_ <strong>Catalog number:</strong> B2016777_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 37.7 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -80°C_x000D_ <strong>Keywords:</strong> Apolipoprotein E3_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C; Alzheimer’s Disease Neuroimaging Initiative; Fagan AM, Miller BL, Boxer AL, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy Nature. 2017 Sep 28;549(7673):523-527._x000D_ 2: Marino C, Perez-Corredor P, O'Hare M, Heuer A, Chmielewska N, Gordon H, Chandrahas AS, Gonzalez-Buendia L, Delgado-Tirado S, Doan TH, Vanderleest TE, Arevalo-Alquichire S, Obar RA, Ortiz-Cordero C, Villegas A, Sepulveda-Falla D, Kim LA, Lopera F, Mahley R, Huang Y, Quiroz YT, Arboleda-Velasquez JF. APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation Alzheimers Dement. 2024 Feb;20(2):819-836._x000D_ 3: Wang S, Li B, Solomon V, Fonteh A, Rapoport SI, Bennett DA, Arvanitakis Z, Chui HC, Sullivan PM, Yassine HN. Calcium-dependent cytosolic phospholipase A(2) activation is implicated in neuroinflammation and oxidative stress associated with ApoE4 Mol Neurodegener. 2022 Jun 15;17(1):42._x000D_ 4: Su M, Xu T, Wang D, Zhou Y, Niu C, Yan W. High yield and purification of recombinant human apolipoprotein E3 in Pichia pastoris Protein Expr Purif. 2009 Nov;68(1):7-11._x000D_ 5: Williams T, Ruiz AJ, Ruiz AM, Vo Q, Tsering W, Xu G, McFarland K, Giasson BI, Sullivan P, Borchelt DR, Chakrabarty P. Impact of APOE genotype on prion-type propagation of tauopathy Acta Neuropathol Commun. 2022 Apr 19;10(1):57._x000D_ 6: Yamamoto T, Ryan RO. Role of leucine zipper motif in apoE3 N-terminal domain lipid binding activity Biochim Biophys Acta. 2006 Sep;1761(9):1100-6._x000D_ 7: Osman E, Evans V, Graham IR, Athanasopoulos T, McIntosh J, Nathwani AC, Simons JP, Dickson G, Owen JS. Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice Atherosclerosis. 2009 May;204(1):121-6._x000D_ 8: Wu H, Yang J, Liu YQ, Lei S, Yang M, Yang Z, Yang Y, Hu Z. Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice J Transl Med. 2021 Mar 4;19(1):97._x000D_ 9: Tran TN, Kim SH, Gallo C, Amaya M, Kyees J, Narayanaswami V. Biochemical and biophysical characterization of recombinant rat apolipoprotein E: similarities to human apolipoprotein E3 Arch Biochem Biophys. 2013 Jan 1;529(1):18-25._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/12042316">10: Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice J Biol Chem. 2002 Aug 16;277(33):29919-26. </a>_x000D_ _x000D_ <strong>Products Related to Human ApoE3 can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>